Literature DB >> 11342626

p27kip protein levels and E2F activity are targets of Cot kinase during G1 phase progression in T cells.

A Velasco-Sampayo1, S Alemany.   

Abstract

Cot/Tpl-2 kinase, homologous to members of mitogen-activated protein kinase kinase kinase, was initially discovered by its capacity to promote cell transformation. Cot/Tpl-2 mRNA levels are increased during G(0) to G(1) phase progression in T lymphocytes, suggesting a role for this kinase later on in the cell cycle. The IL-2-dependent CTLL-2 cells were used to investigate the role of Cot kinase in G(1) to S phase transition. Transient expression of Cot kinase in CTLL-2 cells increases DNA synthesis triggered by IL-2 and the transient expression of a dominant negative form of Cot kinase in CTLL-2 markedly reduces the DNA synthesis triggered by this cytokine. Cell cycle analysis of synchronized CTLL-2 stabling overexpressing Cot kinase indicates that this kinase contributes to the passage to S and G(2)-M phases of the cell cycle. Cot kinase reduces the levels of the cyclin kinase inhibitor p27(kip), whereas bcl-x(L) expression is unaffected. Cot kinase also increases E2F transcriptional activity in a phosphatidylinositol 3 kinase-independent way and acts in synergy with this kinase. These data give evidence, for the first time, of the regulation of different G(1) progression events by Cot kinase.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11342626     DOI: 10.4049/jimmunol.166.10.6084

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  The COOH-terminal domain of wild-type Cot regulates its stability and kinase specific activity.

Authors:  Maria Luisa Gándara; Pilar López; Raquel Hernando; José G Castaño; Susana Alemany
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

2.  Phosphorylation at Thr-290 regulates Tpl2 binding to NF-kappaB1/p105 and Tpl2 activation and degradation by lipopolysaccharide.

Authors:  Jeonghee Cho; Philip N Tsichlis
Journal:  Proc Natl Acad Sci U S A       Date:  2005-02-07       Impact factor: 11.205

3.  Loss of tumor progression locus 2 (tpl2) enhances tumorigenesis and inflammation in two-stage skin carcinogenesis.

Authors:  K L Decicco-Skinner; E L Trovato; J K Simmons; P K Lepage; J S Wiest
Journal:  Oncogene       Date:  2010-10-11       Impact factor: 9.867

4.  A mouse model of uterine leiomyosarcoma.

Authors:  Katerina Politi; Matthias Szabolcs; Peter Fisher; Ana Kljuic; Thomas Ludwig; Argiris Efstratiadis
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

Review 5.  Tumor progression locus 2 (Tpl2) kinase as a novel therapeutic target for cancer: double-sided effects of Tpl2 on cancer.

Authors:  Hye Won Lee; Han Yong Choi; Kyeung Min Joo; Do-Hyun Nam
Journal:  Int J Mol Sci       Date:  2015-02-25       Impact factor: 5.923

Review 6.  Tumor progression locus 2 (TPL2) in tumor-promoting Inflammation, Tumorigenesis and Tumor Immunity.

Authors:  Lucy Wanjiru Njunge; Andreanne Poppy Estania; Yao Guo; Wanqian Liu; Li Yang
Journal:  Theranostics       Date:  2020-07-09       Impact factor: 11.556

7.  Expression of the Tpl2/Cot oncogene in human T-cell neoplasias.

Authors:  Anna V Christoforidou; Helen A Papadaki; Andrew N Margioris; George D Eliopoulos; Christos Tsatsanis
Journal:  Mol Cancer       Date:  2004-12-03       Impact factor: 27.401

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.